• Deferasirox (SKU A8639): Reliable Iron Chelation in Cancer R

  2026-05-20

  This article provides scenario-driven guidance for using Deferasirox (SKU A8639), an oral iron chelator, in cell viability and cancer research assays. Drawing on recent literature and practical workflow insights, it addresses common laboratory challenges—including iron chelation specificity, protocol optimization, and vendor selection—to help researchers achieve reproducible, high-quality results.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-20

  This study reveals that IGF2BP3 stabilizes FZD1/7 mRNAs, enhancing cancer stem-like properties and resistance to carboplatin in triple-negative breast cancer (TNBC). The findings highlight a novel m6A-dependent regulatory mechanism, offering new targets to sensitize TNBC to platinum-based chemotherapy and improve treatment efficacy.

• AM 281: CB1 Cannabinoid Receptor Antagonist in TBI & Memory

  2026-05-19

  AM 281 stands out as a highly selective CB1 cannabinoid receptor antagonist for neuropharmacology, enabling precise modulation in cognitive dysfunction and traumatic brain injury models. Discover nuanced workflow strategies, troubleshooting insights, and direct applications informed by cutting-edge research on the CB1-CREB-GLT-1 axis.

• IMPDH-Dependent Nucleotide Metabolism Drives PEDV Replicatio

  2026-05-19

  The referenced study reveals how porcine epidemic diarrhea virus (PEDV) reprograms host guanine nucleotide metabolism to facilitate viral replication. Pharmacological inhibition or genetic knockdown of inosine monophosphate dehydrogenase (IMPDH) significantly impairs PEDV proliferation, highlighting IMPDH as a promising host-directed antiviral target.

• SIS3 Smad3 Inhibitor: Precision Control in Fibrosis Research

  2026-05-18

  SIS3 is a selective Smad3 inhibitor enabling targeted dissection of the TGF-β pathway in fibrosis, renal, and cancer models. This guide reveals practical workflows, troubleshooting insights, and experimental enhancements to maximize reproducibility and translational relevance using SIS3 from APExBIO.

• 7-Ethyl-10-hydroxycamptothecin: Mechanistic Insights & FUBP1

  2026-05-18

  Explore the dual mechanisms of 7-Ethyl-10-hydroxycamptothecin, a potent SN-38 analog, in advanced colon cancer research. This article delves into FUBP1 pathway inhibition and advanced protocol design, offering new scientific perspectives beyond standard apoptosis and cell cycle arrest workflows.

• Prednisone in Translational Research: Mechanisms, Models, an

  2026-05-17

  This thought-leadership article explores advanced mechanistic insights and actionable strategies for translational researchers using Prednisone, a synthetic corticosteroid, in immunology and neurodegeneration research. Bridging rigorous in vitro validation with strategic workflow optimization, we address the unique roles of Prednisone in cell cycle arrest, IL-2 pathway inhibition, and apoptosis induction in peripheral blood lymphocytes—contrasting its pharmaceutical rigor with the evolving standards of botanical research. Practical protocol parameters, competitive landscape analysis, and forward-looking guidance are provided for investigators seeking reproducibility and translational impact.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-05-16

  Clodronate Liposomes empower researchers to achieve selective, tissue-specific macrophage depletion in complex in vivo models, unlocking new insights into immune cell function and modulation. This article translates cutting-edge experimental workflows and troubleshooting strategies into actionable guidance for maximizing the impact of liposome-encapsulated clodronate in preclinical research.

• Live-Dead Cell Staining Kit: Transforming Cell Viability Ass

  2026-05-15

  The Live-Dead Cell Staining Kit leverages Calcein-AM and Propidium Iodide dual staining for robust, reproducible cell viability analysis in both microscopy and flow cytometry. Its precision and workflow integration surpass single-dye and exclusion methods, empowering translational research from drug cytotoxicity testing to advanced biomaterial evaluation.

• Strategic Cathepsin B Inhibition: Translational Leverage wit

  2026-05-15

  Explore the mechanistic and translational power of selective cathepsin B inhibition in cancer metastasis, neurodegeneration, and immunology. This thought-leadership piece details the evidence, strategic workflow integration, and unique advantages of CA-074 from APExBIO, contextualized by recent advances in necroptosis research.

• PP 1: Selective Src Family Tyrosine Kinase Inhibitor in Canc

  2026-05-14

  PP 1 is a potent and selective Src family tyrosine kinase inhibitor with nanomolar activity against Lck and Fyn, enabling precise modulation of cancer and immune signaling pathways. Its documented selectivity and robust in vitro and in vivo performance make it a critical tool for dissecting oncogenic mechanisms and evaluating immunotherapy strategies.

• Deferoxamine (DeferoxamineB): Iron Chelation in Oncology Res

  2026-05-14

  Deferoxamine (DeferoxamineB) is a potent iron chelator with proven efficacy in reducing iron accumulation and inducing regulated cell death in cancer research. Its robust antioxidant and antiproliferative properties underpin its adoption in advanced biochemical and cell culture assays.

• LncRNA MRF Suppresses BMSC Osteogenesis via cAMP-PKA-CREB Ax

  2026-05-13

  Ning et al. (2025) identify the long non-coding RNA MRF as a negative regulator of osteogenic differentiation in bone marrow mesenchymal stem cells (BMSCs) via modulation of the cAMP-PKA-CREB signaling pathway through FSHR. Their findings clarify a novel molecular mechanism in bone defect repair and propose MRF as a potential target for bone regeneration strategies.

• 2-Hydroxypropyl-β-cyclodextrin: Practical Solubility Guidanc

  2026-05-13

  2-Hydroxypropyl-β-cyclodextrin addresses the challenge of solubilizing poorly water-soluble, hydrophobic research compounds—especially those containing aromatic or phenyl groups—by forming inclusion complexes that enhance their aqueous solubility. It is appropriate for use as a drug formulation excipient or for pharmaceutical solubility improvement, but its application should be restricted to these roles as broader uses are not supported by current product documentation.

• Pemetrexed in Tumor Cell Line Research: Workflows & Insights

  2026-05-12

  Pemetrexed, a multi-targeted antifolate antimetabolite, enables precise modeling of nucleotide biosynthesis disruption in cancer chemotherapy research. This guide delivers stepwise protocols, troubleshooting strategies, and translational insights for maximizing its impact in non-small cell lung carcinoma and malignant mesothelioma models.

11359 records 1/758 page Next 12345 下5页 Last page